ALAMEDA, Calif.--(BUSINESS WIRE)--Preclinical studies using hESCs derived from Advanced Cell Technology, Inc.’s (OTCBB: ACTC) proprietary ACTcellerate technology (a means of accelerating the discovery of products from hESC) will be used as part of a study to determine if hESCs are safe and effective in animal models for heart attacks and heart failure.
